Biogipuzkoa
Centro de investigación
![Foto de Biogipuzkoa](/img/uploaded/BB680065D0326B877226AAACFBE7F51A.png)
![Foto de University of Sydney](/img/noimage_org.png)
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (39)
2024
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
2023
-
Annual (2023) taxonomic update of RNA-directed RNA polymerase-encoding negative-sense RNA viruses (realm Riboviria: kingdom Orthornavirae: phylum Negarnaviricota)
The Journal of general virology, Vol. 104, Núm. 8
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Comparative effectiveness in multiple sclerosis: A methodological comparison
Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332
-
Diminishing benefits of urban living for children and adolescents’ growth and development
Nature, Vol. 615, Núm. 7954, pp. 874-883
-
Disability accrual in primary and secondary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis
European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024
2022
-
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study
Muscle and Nerve, Vol. 65, Núm. 5, pp. 531-540
-
Confirmed disability progression as a marker of permanent disability in multiple sclerosis
European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334
-
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology, Vol. 99, Núm. 17, pp. E1926-E1944
-
Global multi-stakeholder endorsement of the MAFLD definition
The Lancet Gastroenterology and Hepatology
2021
-
Enhanced Eye Velocity With Backup Saccades in vHIT Tests of a Menière Disease Patient: A Case Report
Frontiers in Surgery, Vol. 8
-
Enhanced Eye Velocity in Head Impulse Testing—A Possible Indicator of Endolymphatic Hydrops
Frontiers in Surgery, Vol. 8
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight
eLife, Vol. 10
-
Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease
Neuromuscular Disorders, Vol. 31, Núm. 4, pp. 265-280
-
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis
Neurology, Vol. 96, Núm. 24, pp. E2989-E3002
2020
-
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
The Lancet Neurology, Vol. 19, Núm. 2, pp. 145-156